Lysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma

LPAR6 is the most recently determined G-protein-coupled receptor of the lysophosphatidic acid receptor, and very few of studies have demonstrated the performance of LPAR6 in cancers. Moreover, the relationship of LPAR6 to the potential of prognosis and tumor infiltration immune cells in different ty...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jian He, Rui Gao, Mei Meng, Miao Yu, Chengrong Liu, Jingquan Li, Yizhi Song, Hui Wang
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	LPAR6 lung adenocarcinoma biomarker tumor infiltration lymphocytes prognosis Medicine R
Acceso en línea:	https://doaj.org/article/fc06d96d8d3e47ae9e4c9e9316b94409
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fc06d96d8d3e47ae9e4c9e9316b94409
record_format	dspace
spelling	oai:doaj.org-article:fc06d96d8d3e47ae9e4c9e9316b944092021-11-11T16:11:31ZLysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma10.3390/ijerph1821110381660-46011661-7827https://doaj.org/article/fc06d96d8d3e47ae9e4c9e9316b944092021-10-01T00:00:00Zhttps://www.mdpi.com/1660-4601/18/21/11038https://doaj.org/toc/1661-7827https://doaj.org/toc/1660-4601LPAR6 is the most recently determined G-protein-coupled receptor of the lysophosphatidic acid receptor, and very few of studies have demonstrated the performance of LPAR6 in cancers. Moreover, the relationship of LPAR6 to the potential of prognosis and tumor infiltration immune cells in different types of cancer are still unclarified. In this study, the mRNA expression of LPAR6 and its clinical characteristics were evaluated on various databases. The association between LPAR6 and immune infiltrates of various types of cancer were investigated via TIMER. Immunohistochemistry (IHC) for LPAR6 in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tissue microarray with patients’ information was detected. We constructed a systematic prognostic landscape in a variety of types of cancer base on the expression level of mRNA. We enclosed that higher LPAR6 mRNA expression level was associated with better overall survival in some types of malignancy. Moreover, LPAR6 significantly affects the prognostic potential of various cancers in The Cancer Genome Atlas Program (TCGA), especially in lung cancer. Tissue microarrays of lung cancer patient cohorts demonstrated that a higher protein level of LPAR6 was correlated to better overall survival of LUAD rather than LUSC cohorts. Further research indicated that the underlying mechanism of this phenome might be the mRNA expression level of LPAR6 was positively associated to infiltrating statuses of devious immunocytes in LUAD rather than in LUSC, that is, LPAR6 expression potentially contributes to the activation and recruiting of T cells (CD8+ T, naive T, effector T cell) and NK cells and inactivates Tregs, decreases T cell exhaustion and regulates T-helper (Th) cells in LUAD. Our discovery implies that LPAR6 is associated with prognostic potential and immune-infiltrating levels in LUAD. These discoveries imply that LPAR6 could be a promising novel biomarker for indicating the prognosis potential of LUAD patients.Jian HeRui GaoMei MengMiao YuChengrong LiuJingquan LiYizhi SongHui WangMDPI AGarticleLPAR6lung adenocarcinomabiomarkertumor infiltration lymphocytesprognosisMedicineRENInternational Journal of Environmental Research and Public Health, Vol 18, Iss 11038, p 11038 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	LPAR6 lung adenocarcinoma biomarker tumor infiltration lymphocytes prognosis Medicine R
spellingShingle	LPAR6 lung adenocarcinoma biomarker tumor infiltration lymphocytes prognosis Medicine R Jian He Rui Gao Mei Meng Miao Yu Chengrong Liu Jingquan Li Yizhi Song Hui Wang Lysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma
description	LPAR6 is the most recently determined G-protein-coupled receptor of the lysophosphatidic acid receptor, and very few of studies have demonstrated the performance of LPAR6 in cancers. Moreover, the relationship of LPAR6 to the potential of prognosis and tumor infiltration immune cells in different types of cancer are still unclarified. In this study, the mRNA expression of LPAR6 and its clinical characteristics were evaluated on various databases. The association between LPAR6 and immune infiltrates of various types of cancer were investigated via TIMER. Immunohistochemistry (IHC) for LPAR6 in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tissue microarray with patients’ information was detected. We constructed a systematic prognostic landscape in a variety of types of cancer base on the expression level of mRNA. We enclosed that higher LPAR6 mRNA expression level was associated with better overall survival in some types of malignancy. Moreover, LPAR6 significantly affects the prognostic potential of various cancers in The Cancer Genome Atlas Program (TCGA), especially in lung cancer. Tissue microarrays of lung cancer patient cohorts demonstrated that a higher protein level of LPAR6 was correlated to better overall survival of LUAD rather than LUSC cohorts. Further research indicated that the underlying mechanism of this phenome might be the mRNA expression level of LPAR6 was positively associated to infiltrating statuses of devious immunocytes in LUAD rather than in LUSC, that is, LPAR6 expression potentially contributes to the activation and recruiting of T cells (CD8+ T, naive T, effector T cell) and NK cells and inactivates Tregs, decreases T cell exhaustion and regulates T-helper (Th) cells in LUAD. Our discovery implies that LPAR6 is associated with prognostic potential and immune-infiltrating levels in LUAD. These discoveries imply that LPAR6 could be a promising novel biomarker for indicating the prognosis potential of LUAD patients.
format	article
author	Jian He Rui Gao Mei Meng Miao Yu Chengrong Liu Jingquan Li Yizhi Song Hui Wang
author_facet	Jian He Rui Gao Mei Meng Miao Yu Chengrong Liu Jingquan Li Yizhi Song Hui Wang
author_sort	Jian He
title	Lysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma
title_short	Lysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma
title_full	Lysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma
title_fullStr	Lysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma
title_full_unstemmed	Lysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma
title_sort	lysophosphatidic acid receptor 6 (lpar6) is a potential biomarker associated with lung adenocarcinoma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/fc06d96d8d3e47ae9e4c9e9316b94409
work_keys_str_mv	AT jianhe lysophosphatidicacidreceptor6lpar6isapotentialbiomarkerassociatedwithlungadenocarcinoma AT ruigao lysophosphatidicacidreceptor6lpar6isapotentialbiomarkerassociatedwithlungadenocarcinoma AT meimeng lysophosphatidicacidreceptor6lpar6isapotentialbiomarkerassociatedwithlungadenocarcinoma AT miaoyu lysophosphatidicacidreceptor6lpar6isapotentialbiomarkerassociatedwithlungadenocarcinoma AT chengrongliu lysophosphatidicacidreceptor6lpar6isapotentialbiomarkerassociatedwithlungadenocarcinoma AT jingquanli lysophosphatidicacidreceptor6lpar6isapotentialbiomarkerassociatedwithlungadenocarcinoma AT yizhisong lysophosphatidicacidreceptor6lpar6isapotentialbiomarkerassociatedwithlungadenocarcinoma AT huiwang lysophosphatidicacidreceptor6lpar6isapotentialbiomarkerassociatedwithlungadenocarcinoma
_version_	1718432393428205568

Lysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma

Ejemplares similares